[A case of RAEB-t treated by G-CSF showing complete remission after MST-16 treatment for subsequent reversible leukemia].

A seventy-five-year-old female with general fatigue, high fever and anemia was admitted. Her chest X-ray film revealed pneumonia. She was diagnosed as RAEB-t with the normal karyotype by peripheral blood film and bone marrow aspiration; 125 micrograms/ml of G-CSF was administered s.c. daily in order to increase neutrophil count because of the prolongation of pneumonia. Her blast cells in both peripheral blood and bone marrow showed a remarkable increase by G-CSF. After the cessation of G-CSF administration, blast cells decreased rapidly, and neutrophil count in the peripheral blood increased. Her pneumonia was then cured. After 5 months of stable hematological state, 60% of her bone marrow cells became occupied by blast cells again. So 2 consecutive courses of 14 days p.o. administration of 1,200 mg MST-16/day were tried. Three months after the first MST-16 trial, her bone marrow showed complete remission (CR) which lasted about 4 months. But she died of sepsis after the first relapse. Her bone marrow in CR still revealed several features of dyspoiesis.
AuthorsT Murate, H Ohashi, Y Kagami, T Hotta, T Murase, Y Hirota, K Kimura
JournalGan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 18 Issue 12 Pg. 2155-8 (Sep 1991) ISSN: 0385-0684 [Print] JAPAN
PMID1716093 (Publication Type: Case Reports, English Abstract, Journal Article)
Chemical References
  • Antineoplastic Agents
  • Piperazines
  • Granulocyte Colony-Stimulating Factor
  • sobuzoxane
  • Acute Disease
  • Administration, Oral
  • Aged
  • Anemia, Refractory, with Excess of Blasts (pathology, therapy)
  • Antineoplastic Agents (administration & dosage, therapeutic use)
  • Bone Marrow (pathology)
  • Clone Cells
  • Female
  • Granulocyte Colony-Stimulating Factor (administration & dosage, therapeutic use)
  • Humans
  • Leukemia (drug therapy, pathology)
  • Leukocyte Count
  • Neutrophils
  • Piperazines (administration & dosage, therapeutic use)
  • Remission Induction

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: